A Phase 2 interventional study of Ingavirin Forte, 90 mg + 5 mg, Capsules and Ingavirin Forte, 90 mg + 10 mg, Capsules in Influenza and Acute Respiratory Viral Infection, sponsored by Valenta Pharm JSC. Recruiting at 11 sites in Russia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Valenta Pharm JSC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 2, and was the 14th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 300 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 240 across the 15 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs).
Inclusion Criteria:
Presence of signs of influenza or acute respiratory viral infections at screening:
Consent to use adequate methods throughout the study and for 30 days after study completion. The follwing subjects are eligible for inclusion in the study:
Exclusion Criteria:
Exclusion Criteria:
Major deviation from the treatment regimen, defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Ingavirin Forte, 90 mg + 5 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Drug: Ingavirin Forte, 90 mg + 5 mg, Capsules
Subjects will receive Ingavirin Forte, 90 mg + 10 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Drug: Ingavirin Forte, 90 mg + 10 mg, Capsules
Subjects will receive Ingavirin Forte, 90 mg + 20 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Drug: Ingavirin Forte, 90 mg + 20 mg, Capsules
Subjects will receive Ingavirin, 90 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Drug: Ingavirin, 90 mg, Capsules
Subjects will receive Placebo, 1 capsule twice daily (morning and evening), for 5 consecutive days.
Drug: Placebo
90 mg + 5 mg, 1 capsule twice a day, for 5 days
Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid
90 mg + 10 mg, 1 capsule twice a day, for 5 days
Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid
90 mg + 20 mg,1 capsule twice a day, for 5 days
Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid
90 mg, 1 capsule twice a day, for 5 days
Also known as: Imidazolyl ethanamide pentandioic acid
1 capsule twice a day, for 5 days
Time (in hours) from the first dose of the study drug to the sustained resolution of all the following symptoms/events (with each resolved symptom/event persisting for at least 24 hours without the use of NSAIDs and/or decongestants):
* fever (the first time point at which body temperature remains stably normalized (\<37.0°C) for 24 h); * runny nose/rhinorrhoea (the first time point with Numeric Rating Scale (NRS) ≤ 2 which maintained for ≥24 h); * nasal congestion/stuffiness (the first time point with NRS ≤ 2 which maintained for ≥24 h); * sore throat (the first time point with NRS ≤ 2 which maintained for ≥24 h); * throat irritation (the first time point with NRS ≤ 2 which maintained for ≥24 h); * cough (the first time point with NRS ≤ 2 which maintained for ≥24 h); * generalized weakness/malaise (the first time point with NRS ≤ 2 which maintained for ≥24 h); * headache (the first time point with NRS ≤ 2 which maintained for ≥24 h); * myalgia (the first time point with NRS ≤ 2 which maintained for ≥24 h).
Time frame: Day 1 - Day 10 of the study.
Mean daily symptom severity score based on the NRS (arithmetic mean of the scores over a 24-hour period). A "day" will be calculated as 24-hour intervals starting from the time of the first dose administration.
* fever (arithmetic mean of the daily scores); * runny nose/rhinorrhoea (arithmetic mean of the daily scores); * nasal congestion/stuffiness (arithmetic mean of the daily scores); * sore throat (arithmetic mean of the daily scores); * throat irritation (arithmetic mean of the daily scores); * cough (arithmetic mean of the daily scores); * generalized weakness/malaise (arithmetic mean of the daily scores); * headache (arithmetic mean of the daily scores); * myalgia (arithmetic mean of the daily scores).
Time frame: Day 1 - Day 10 of the study.
Time (in hours) from first dose of study drug to resolution of disease symptoms.
* fever (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * runny nose/rhinorrhoea (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * nasal congestion/stuffiness (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * sore throat (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * throat irritation (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * cough (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * generalized weakness/malaise (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * headache (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * myalgia (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h).
Time frame: Day 1 - Day 10 of the study.
Proportion of subjects using intranasal decongestant spray for nasal obstruction relief at Visit 2 (Day 3) and Visit 3 (Day 6).
Rate of nasal decongestant spray use for symptomatic relief of nasal obstruction.
Time frame: Day 3, Day 6 of the study.
Mean daily frequency of decongestant nasal spray use at Visit 2 (Day 3) and Visit 3 (Day 6).
The mean daily frequency of decongestant use will be calculated for each subject as the total number of administrations from the first dose of the investigational product up to the target visit, divided by the number of days in that period.
Time frame: Day 3, Day 6 of the study.
Proportion of subjects using analgesic and/or NSAID medications at Visit 2 (Day 3) and Visit 3 (Day 6).
Rate of using analgesic and/or NSAID medications to relif symptoms of Influenza or ARVI.
Time frame: Day 3, Day 6
Mean daily frequency of analgesic and/or NSAID use at Visit 2 (Day 3) and Visit 3 (Day 6).
The mean daily frequency of analgesic and/or NSAID use will be calculated for each subject as the total number of administrations from the first dose of the investigational product up to the target visit, divided by the number of days in that period.
Time frame: Day 3, Day 6 of the study.
Proportion of subjects with viral elimination by Visit 3 (Day 6).
Proportion of subjects with a negative PCR test result
Time frame: Day 6 of the study.
Assessment of clinical sign severity via pharyngoscopy at Visit 2 (Day 3) and Visit 3 (Day 6).
* Assessment of the severity of hyperemia and ridge-like thickening of the edges of the palatine arches; * Assessment of the severity of caseous-purulent plugs or liquid pus in the tonsillar lacunae; * Assessment of the severity of edema of the tonsils; * Assessment of the severity of edema of the palatine arches; * Assessment of the severity of edema of the uvula; * Assessment of the severity of edema of the posterior pharyngeal wall. Each symptom will be assessed on a 4-point severity scale, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.
Time frame: Day 3, Day 6 of the study.
Assessment of clinical sign severity via rhinoscopy at Visit 2 (Day 3) and Visit 3 (Day 6).
* Assessment of the severity of nasal discharge * Assessment of the severity of nasal mucosal hyperemia * Assessment of the severity of nasal mucosal edema Each symptom will be assessed on a 4-point severity scale, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.
Time frame: Day 3, Day 6 of the study.
Assessment of treatment effectiveness by the Investigator on a 5-point scale at Visit 2 (Day 3) and Visit 3 (Day 6).
A 5-point scale will be used to assess treatment effectiveness, where: 1 point - absence of clinical symptoms, 2 points - regression of the main clinical symptoms, 3 points - reduction in the severity of clinical symptoms, 4 points - lack of positive dynamics of clinical symptoms, 5 points - worsening of clinical symptoms.
Time frame: Day 3, Day 6 of the study.
Subject's assessment of treatment effectiveness on a 5-point scale at Visit 2 (Day 3) and Visit 3 (Day 6).
To assess treatment effectiveness from the subject's perspective, a 5-point scale will be used, where: 1 point - poor, 2 points - satisfactory, 3 points - good, 4 points - very good, 5 points - excellent.
Time frame: Day 3, Day 6 of the study.
Safety and Tolerability: adverse events rate
Number and frequency of adverse events and serious adverse events.
Time frame: Screening (Day-1), and from Day 1 to Day 10
Safety and Tolerability: adverse events associated with the study drug
Number and frequency of adverse events associated with the study drug.
Time frame: From Day 1 to Day 10
Safety and Tolerability: serious adverse events associated with the study drug
Number and frequency of serious adverse events associated with the study drug.
Time frame: From Day 1 to Day 10
Safety and Tolerability: proportion of subjects with at least one adverse event.
Proportion of subjects with one or more adverse events.
Time frame: Screening (Day-1), and from Day 1 to Day 10
Safety and Tolerability: treatment discontinuation
roportion of subjects who discontinued treatment due to an adverse events.
Time frame: From Day 1 to Day 10
Safety and Tolerability: vital signs - systolic blood pressure (SBP)
SBP, mmHg
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: vital signs - diastolic blood pressure (DBP)
DBP, mmHg
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: vital signs - respiratory rate (RR)
RR, breaths per minute
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: vital signs - body temperature
Body temperature, Celsius temperature scale
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Subject complaints
Description of complaints, recieved from subject
Time frame: Screening (Day-1), and from Day 1 to Day 10
Physical examination results - cardiovascular system
An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - respiratory system
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - digestive tract
An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - endocrine system
An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - musculoskeletal system
An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - nervous system
An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - skin/visible mucous membranes
An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - genitourinary system
An assessment of the condition of the genitourinary system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - otorhinolaryngological organs
An assessment of the condition of the otorhinolaryngological organs on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Physical examination results - organ of vision
An assessment of the condition of the organ of vision on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: complete blood count - hemoglobin
Hemoglobin, g/dL
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: complete blood count - hematocrit
Hematocrit, %
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: complete blood count - red blood cells
Red blood cell count (cells/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - leukocyte count
Leukocyte count (cells/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - platelet count
Platelet count (cells/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate
Erythrocyte sedimentation rate (mm/h)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - band neutrophils
Leukocyte formula (band neutrophils, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - segmented neutrophils
Leukocyte formula (segmented neutrophils, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - eosinophils
Leukocyte formula (eosinophils, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - basophils
Leukocyte formula (basophils, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - monocytes
Leukocyte formula (monocytes, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: clinical blood test - lymphocyte
eukocyte formula (lymphocytes, %)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - alanine transaminase
Alanine transaminase activity (U/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - aspartate transaminase
Aspartate transaminase activity (U/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - bilirubin
Total bilirubin concentration (micromol/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - glucose
Glucose concentration (mmol/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - total protein
Total protein in blood serum (g/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - creatinine
Creatinine concentration (micromol/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: blood chemistry - urea
Urea in blood serum (mmol/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
C-reactive protein (CRP)
Serum C-reactive protein (mg/L))
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - pH
pH of the urine
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - specific gravity
Specific gravity of the urine
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - protein
Protein concentration (g/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - glucose
Glucose concentration (mmol/L)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - red blood cells
Red blood cell content (number in sight)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Safety and Tolerability: urinalysis - white blood cells
White blood cell content (number in sight)
Time frame: Screening, Day 3, Day 6, and Day 10 of the study.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 26 months is above that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.